Rockwell Medical’s (RMTI) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Rockwell Medical (NASDAQ:RMTI) in a research note issued to investors on Friday,Benzinga reports. They currently have a $20.00 price objective on the stock. HC Wainwright also issued estimates for Rockwell Medical’s Q1 2027 earnings at $0.02 EPS, Q4 2027 earnings at $0.14 EPS and FY2027 earnings at $0.36 EPS.

A number of other equities research analysts also recently commented on the stock. Weiss Ratings raised shares of Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 3rd. Wall Street Zen raised Rockwell Medical to a “hold” rating in a report on Saturday, July 25th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Rockwell Medical has an average rating of “Hold” and an average price target of $20.00.

Rockwell Medical Price Performance

RMTI opened at $7.96 on Friday. The company’s 50-day simple moving average is $7.12 and its two-hundred day simple moving average is $7.84. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.00 and a current ratio of 3.25. The stock has a market capitalization of $32.08 million, a P/E ratio of -5.94 and a beta of 1.64. Rockwell Medical has a 52-week low of $4.89 and a 52-week high of $17.20.

Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). The company had revenue of $17.78 million during the quarter, compared to the consensus estimate of $17.82 million. Rockwell Medical had a negative return on equity of 14.03% and a negative net margin of 7.33%. As a group, analysts predict that Rockwell Medical will post -0.76 EPS for the current year.

Institutional Trading of Rockwell Medical

Large investors have recently added to or reduced their stakes in the business. Corsair Capital Management L.P. purchased a new stake in Rockwell Medical during the first quarter valued at approximately $45,000. Renaissance Technologies LLC raised its position in Rockwell Medical by 36.5% in the first quarter. Renaissance Technologies LLC now owns 639,120 shares of the company’s stock worth $571,000 after acquiring an additional 170,800 shares during the period. XTX Topco Ltd boosted its stake in shares of Rockwell Medical by 286.5% during the 4th quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock worth $52,000 after acquiring an additional 46,029 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Rockwell Medical during the 4th quarter worth $84,000. Finally, Geode Capital Management LLC grew its position in shares of Rockwell Medical by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after acquiring an additional 41,668 shares during the period. 23.31% of the stock is currently owned by institutional investors.

About Rockwell Medical

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.